Ascendis Pharma A/S
TransCon CNP
pediatric achondroplasia
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews TransCon CNP for pediatric achondroplasia around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 6-K
verified 12h ago
“Held a successful end of Phase 2 meeting with the U.S. Food & Drug Administration (FDA) and Scientific Advice meeting in the EU regarding a Phase 3 trial of TransCon CNP and TransCon hGH in pediatric achondroplasia in the fourth quarter of ”